Novocure Q2 net revenue $126M (-11% YoY); phase 3 LUNAR NSCLC trial meets primary endpoint

NovoCure Ltd

2023-Q2 EPS reported -$1.04 revenue$248,233,000

Net loss $57.4M ($0.54 per share); adjusted EBITDA -$27.2M; active patients 3,571.
LUNAR trial: median OS 13.2 months TTFields+standard vs 9.9 months standard alone (HR=0.74, p=0.035).
Revenue decline largely due to $13.4M reduced collections from previously denied U.S. claims.
Prescriptions up 13% to 1,556; U.S., Germany, Japan contributed 981, 204, and 92 respectively.
PANOVA-3 (pancreatic) DMC recommends proceeding to final analysis; LUNAR-2 trial IDE accepted by FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NovoCure Ltd reported the quarter ended June 30, 2023 results: revenue $126.1 million, net income $57.4 million, EPS $0.54.

Period: the quarter ended June 30, 2023
Revenue: $126.1 million
Net income: $57.4 million
EPS: $0.54
Result: reported results

Exact text from the filing

30, 2023. A copy of the press release is attached as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- Novocure Reports Second Quarter 2023 Financial Results Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four

View on SEC.gov

Browse all earnings releases →

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.